Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
Accession Number
DB14385
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)unknownW45Z4CJE2JNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FluarixInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-162009-07-15Us
Fluarix 2010/2011Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2010-08-092010-08-02Us
Categories
UNII
166D8OWM7B
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionFlu caused by Influenza1
1Active Not RecruitingPreventionInfluenza, Human1
1CompletedPreventionFlu caused by Influenza2
1CompletedPreventionFlu caused by Influenza / Influenza Vaccines / Seasonal Influenza1
1CompletedPreventionFlu caused by Influenza / Influenzae Disease1
1CompletedPreventionHealthy Volunteers1
1, 2Active Not RecruitingTreatmentFlu caused by Influenza1
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma1
2CompletedPreventionFlu caused by Influenza14
2CompletedPreventionFlu caused by Influenza / Influenza Infection2
2CompletedPreventionFlu caused by Influenza / Influenza Vaccines2
2CompletedPreventionFlu caused by Influenza / Influenza, Human1
2CompletedPreventionFlu caused by Influenza / Pandemic Flu1
2CompletedPreventionHealthy Volunteers1
2TerminatedPreventionFlu caused by Influenza / Influenza Disease1
2, 3WithdrawnPreventionHuman Immunodeficiency Virus (HIV) / Influenza, Human / Plasmodium Infections / Poliomyelitis / Tetanus1
3Active Not RecruitingPreventionFlu caused by Influenza1
3CompletedPreventionAcellular Pertussis / Diphtheria / Flu caused by Influenza / Pertussis / Tetanus1
3CompletedPreventionFlu caused by Influenza21
3CompletedPreventionFlu caused by Influenza / Influenza A Virus, H1N1 Subtype / Influenza Infection1
3CompletedPreventionFlu caused by Influenza / Influenza Disease / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Influenza Infection2
3CompletedPreventionFlu caused by Influenza / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Seasonal Influenza3
3CompletedPreventionHerpes Zoster1
3CompletedPreventionInfections, Pneumococcal1
3CompletedPreventionInfluenza, Human1
3CompletedPreventionMeningococcal Infections1
4Active Not RecruitingBasic ScienceInfluenza A Subtype H5N1 Infection1
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedHealth Services ResearchInfluenza, Human / Pneumonia1
4CompletedOtherAsthma / Influenza Vaccines in Asthma Populations1
4CompletedPreventionFlu caused by Influenza5
4CompletedPreventionFlu caused by Influenza / Influenza Infection2
4RecruitingPreventionFlu caused by Influenza / Influenza immunisation1
Not AvailableActive Not RecruitingNot AvailableAstrocytomas / Gliomas / Oligodendrogliomas1
Not AvailableCompletedNot AvailableFlu caused by Influenza2
Not AvailableCompletedBasic ScienceImmune Response1
Not AvailableCompletedPreventionInfluenza, Human2
Not AvailableRecruitingBasic ScienceAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
Not AvailableRecruitingBasic ScienceInfluenza, Human1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 05, 2018 12:02 / Updated on December 02, 2019 10:12